Searched for
PFIZER OBESITY TREATMENT
From oncology to obesity, Pfizer bets big on India for its next growth wavePfizer is prioritizing India for future growth. The company plans to launch new medicines here soon after their global release. Pfizer aims...- Eli Lilly brings monthly Alzheimer's therapy donanemab to India at ₹91,688 per vialEli Lilly is making Alzheimer's a major focus for its future innovations. The company is also expanding its specialty medicine offerings in...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- US market today: Pfizer posts strong first-quarter, sees boost from recent legal winsPfizer reported higher-than-expected sales and profit on Tuesday and said a patent extension for its Vyndamax heart drug and a recent favor...
- Why is PFE stock falling today despite beating Pfizer's earnings estimates? Key factors investors are watchingPFE stock today: Pfizer's stock dipped despite strong fourth-quarter earnings. Investors reacted to the company's modest 2026 outlook. Decl...
- Eli Lilly becomes first healthcare firm to hit $1 trillion market cap - here’s why LLY stock has jumped over 36% this yearEli Lilly stock today: Eli Lilly achieved a historic milestone, briefly touching a $1 trillion market cap. This success is driven by strong...
- Weight-loss treatment: How has obesity medicine market become battleground for pharma giants like Pfizer, AstraZeneca, Eli Lilly?Obesity, weight-loss medicines: Novo has been scrambling to keep pace in the obesity drug race it started, losing ground to rival Eli Lilly...
- Pfizer to acquire obesity drug startup Metsera in $10 billion dealPfizer has agreed to acquire obesity drug developer Metsera for up to $86.25 a share, surpassing Novo Nordisk's final offer. This move mark...
- Pfizer weighs sweeter offer for Metsera after Judge blocks bid to halt Novo Nordisk’s $10 billion takeoverPfizer is increasing its offer for Metsera. This comes after a judge rejected Pfizer's attempt to stop rival Novo Nordisk's bid. Pfizer's d...
- Pfizer, Novo Nordisk escalate bidding war for obesity drug developer MetseraA fierce bidding war is underway for Metsera, an obesity drug developer. Novo Nordisk has made a $10 billion offer, which Metsera considers...
- Pfizer agrees to lower prescription drug costs for Medicaid in a deal with TrumpPfizer agreed to lower drug costs and invest $70 billion in U.S. manufacturing following a deal with the Trump administration. The drugmake...
- PFE stock rises 5.3% today: Pfizer seals Trump drug price deal with $70 billion U.S. investment and $7.3 billion Metsera weight-loss acquisitionPfizer Inc. (NYSE: PFE) experienced a significant uptick in its stock price following two major announcements on September 30, 2025. Presid...
- Pfizer PFE stock, Metsera MTSR stock: Pfizer, Metsera share prices jump as deal worth over $7 billion gets thumbs upStock Market boom for both companies' shares came as Pfizer said on Monday it would acquire drug developer Metsera in a deal valued at up t...
- Obesity drugs gain weight in labs: Several clinical trials by big and small pharma cos underwayDriven by the success of Wegovy and Mounjaro, numerous pharma companies are developing anti-obesity drugs, with over 170 in various stages....
- Pfizer ends development of weight-loss pill danuglipronPfizer has halted the development of its experimental weight-loss pill, danuglipron, following a trial participant's liver injury, which re...
- Pfizer confirms COVID pill's results, potency versus omicronThe Food and Drug Administration is expected to soon rule on whether to authorize Pfizer's pill and a competing pill from Merck, which was ...
- Pfizer says antiviral pill cuts risk of severe COVID-19 by 89%Pfizer said it plans to submit interim trial results for its pill, which is given in combination with an older antiviral called ritonavir, ...
- Boehringer may buy Pfizer's animal health businessIn July last year, the world's second biggest pharma company, Pfizer had announced a spin off of its animal health and nutrition business.
- Pfizer’s Q3 profit up on downsizing, higher salesPfizer, the world’s biggest drugmaker, said profit tripled because of higher sales of the pain pill Lyrica and lower costs from the 11,000 ...
- Pfizer shifts focus to cancer and biotech drugsPfizer Inc. is shifting its research focus to diseases that have high potential for big profits and for treatment improvements, such as can...
Load More
